Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
PR Newswire —
ANN ARBOR, Mich., Jan. 6, 2026 /PRNewswire/ -- Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Cell Metabolism of groundbreaking preclinical data demonstrating that its lead compound, EVT0185, a...